Haemophilus influenzae type b conjugate vaccines: Considerations for vaccination schedules and implications for developing countries

Human Vaccines

Volumn 6, Issue 10, 2010, Pages 810-818

  Fitzwater, Sean P ^a,b   Watt, James P ^a,b   Levine, Orin S ^a   Santosham, Mathuram ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Hib Initiative   (United States)

Author keywords

Conjugate vaccine; Developing countries; Haemophilus influenzae type b; Vaccine schedule

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

BACTERIAL MENINGITIS; DEVELOPING COUNTRY; DRUG DOSE REGIMEN; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFECTION PREVENTION; REVIEW; VACCINATION;

DEVELOPING COUNTRIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; VACCINES, CONJUGATE;

EID: 78649338859     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.10.13017     Document Type: Review

References (81)

1. Chandran A, Watt JP, Santosham M. Prevention of Haemophilus influenzae type b disease: past success and future challenges. Expert Rev Vaccines 2005; 4:819-27.
2. Bijlmer HA. World-wide epidemiology of Haemophilus influenzae meningitis; industrialized versus non-industrialized countries. Vaccine 1991; 9:5-9.
3. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374:903-11.
4. Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev 2007; 001729.
5. Decker MD, Edwards KM. Haemophilus influenzae type b vaccines: history, choice and comparisons. Pediatr Infect Dis J 1998; 17:113-6.
6. Robbins JB, Parke JC Jr, Schneerson R, Whisnant JK. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res 1973; 7:103-10.
7. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.
8. Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984; 310:1561-6. (Pubitemid 14117336)
9. Fernandez J, Levine OS, Sanchez J, Balter S, LaClaire L, Feris J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 2000; 182:1553-6.
10. Baggett HC, Hennessy TW, Bulkow L, Romero-Steiner S, Hurlburt D, Holder P, et al. Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska. Clin Vaccine Immunol 2006; 13:620-6.
11. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120:184-9.
12. The Immunological Basis for Immunization Series. Geneva: World Health Organization - Department of Immunization, Vaccines and Biologicals 2007.
13. Martin M, Casellas JM, Madhi SA, Urquhart TJ, Delport SD, Ferrero F, et al. Impact of haemophilus influenzae type b conjugate vaccine in South Africa and Argentina. Pediatr Infect Dis J 2004; 23:842-7.
14. Baqui AH, El Arifeen S, Saha SK, Persson L, Zaman K, Gessner BD, et al. Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J 2007; 26:565-71.
15. Muganga N, Uwimana J, Fidele N, Gahimbare L, Gessner BD, Mueller JE, et al. Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda. Vaccine 2007; 25:7001-5.
16. Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005; 366:144-50.
17. Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 2000; 29:753-6.
18. Verghese VP, Friberg IK, Cherian T, Raghupathy P, Balaji V, Lalitha MK, et al. Community effect of Haemophilus influenzae type b vaccination in India. Pediatr Infect Dis J 2009; 28:738-40.
19. Diez-Domingo J, Pereiro I, Morant A, Gimeno C, San-Martin M, Gonzalez A. Impact of non-routine vaccination on the incidence of invasive Haemophilus influenzae type b (Hib) disease: experience in the autonomous region of Valencia, Spain. J Infect 2001; 42:257-60.
20. Mohle-Boetani JC, Ajello G, Breneman E, Deaver KA, Harvey C, Plikaytis BD, et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 1993; 12:589-93.
21. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995; 171:93-8.
22. Daza P, Banda R, Misoya K, Katsulukuta A, Gessner BD, Katsande R, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006; 24:6232-9.
23. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008; 93:665-9.
24. Blanchard-Rohner G, Pollard AJ. Sustaining immunity after immunization against encapsulated bacteria. Hum Vaccin 2008; 4:309-12.
25. Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States 1987-1995. MMWR Morb Mortal Wkly Rep 1996; 45:901-6.
26. Kriz P, Lebedova V, Benes C. Large decrease in incidence of invasive Haemophilus influenzae b disease following introduction of routine vaccination in the Czech Republic. Euro Surveill 2005; 10:050728 4.
27. Wang H, Deeks S, Glasswell A, McIntyre P. Trends in invasive Haemophilus influenzae type B disease in Australia 1995-2005. Commun Dis Intell 2008; 32:316-25.
28. Lewis RF, Kisakye A, Gessner BD, Duku C, Odipio JB, Iriso R, et al. Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ 2008; 86:292-301.
29. Progress introducing Haemophilus influenzae type b vaccine in low-income countries 2004-2008. Wkly Epidemiol Rec 2008; 83:61-7.
30. O'Loughlin RE, Hajjeh R. Accelerating Haemophilus influenzae type b vaccine introduction in the world's poorest countries: a dream is coming true. Future Microbiol 2008; 3:377-8.
31. Jadhav S, Datla M, Kreeftenberg H, Hendriks J. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 2008; 26:1611-5.
32. Vaccine Information Management System. International Vaccine Access Center: Johns Hopkins Bloomberg School of Public Health. Accessed 2009.
33. WHO vaccine-preventable diseases: monitoring system 2009 global summary. Geneva: World Health Organization - Department of Immunization. Vaccines and Biologicals 2009.
34. Gessner BD. Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Rev Vaccines 2009; 8:91-102.
35. Hviid A. Postlicensure epidemiology of childhood vaccination: the Danish experience. Expert Rev Vaccines 2006; 5:641-9.
36. Trotter CL, McVernon J, Ramsay ME, Whitney CG, Mulholland EK, Goldblatt D, et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008; 26:4434-45.
37. Ladhani S, Heath PT, Slack MP, McIntyre PB, Diez-Domingo J, Campos J, et al. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin Microbiol Infect 2009.
38. Takala AK, Santosham M, Almeido-Hill J, Wolff M, Newcomer W, Reid R, et al. Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1993; 12:593-9.
39. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 1998; 177:1758-61.
40. Calandra GB, Lukacs LJ, Jonas LC, Santosham M, Ward JI, Greenberg DP, et al. Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses. Vaccine 1993; 11:58-62.
41. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. Washington DC: Public Health Foundation 2008.
42. Eskola J, Kayhty H. Early immunization with conjugate vaccines. Vaccine 1998; 16:1433-8.
43. Lieberman JM, Greenberg DP, Wong VK, Partridge S, Chang SJ, Chiu CY, et al. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J Pediatr 1995; 126:198-205.
44. Kurikka S, Kayhty H, Peltola H, Saarinen L, Eskola J, Makela PH. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatrics 1995; 95:815-22.
45. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349:1191-7.
46. Mulholland K, Suara RO, Siber G, Roberton D, Jaffar S, N'Jie J, et al. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. JAMA 1996; 275:1182-8.
47. Santosham M, Englund JA, McInnes P, Croll J, Thompson CM, Croll L, et al. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatr Infect Dis J 2001; 20:931-40.
48. Englund JA, Glezen WP, Turner C, Harvey J, Thompson C, Siber GR. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. J Infect Dis 1995; 171:99-105.
49. Sow SO, Tapia MD, Diallo S, Keita MM, Sylla M, Onwuchekwa U, et al. Haemophilus influenzae Type B conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. Am J Trop Med Hyg 2009; 80:1033-8.
50. Cisse MF, Breugelmans JG, Ba M, Diop MB, Faye PC, Mhlanga B, et al. The Elimination of Haemophilus influenzae type b Meningitis Following Conjugate Vaccine Introduction in Senegal. Pediatr Infect Dis J 2009.
51. Clark A, Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009; 373:1543-9.
52. Huebner RE, Nicol M, Mothupi R, Kayhty H, Mbelle N, Khomo E, et al. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 2004; 23:802-6.
53. Nicol M, Huebner R, Mothupi R, Kayhty H, Mbelle N, Khomo E. Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial. Pediatr Infect Dis J 2002; 21:138-41.
54. Punjabi NH, Richie EL, Simanjuntak CH, Harjanto SJ, Wangsasaputra F, Arjoso S, et al. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants. Vaccine 2006; 24:1776-85.
55. Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, et al. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 1998; 351:1472-6.
56. Capeding MR, Nohynek H, Kayhty H, Pascual LG, Sunico ES, Tamundong AA, et al. Antibody responses of three Haemophilus influenzae type b conjugate vaccines after one, two and three doses in Filipino children. Vaccine 1998; 16:1004-8.
57. Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993; 12:484-92.
58. Singleton R, Hammitt L, Hennessy T, Bulkow L, DeByle C, Parkinson A, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 2006; 118:421-9.
59. Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324:1767-72.
60. Levine OS, Granoff DM, Lagos R, Fritzell B, Levine MM. Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. Vaccine 1997; 15:325-8.
61. Eskola J, Peltola H, Kayhty H, Takala AK, Makela PH. Finnish efficacy trials with Haemophilus influenzae type b vaccines. J Infect Dis 1992; 165:137-8.
62. Heath PT, Booy R, Azzopardi HJ, Slack MP, Bowen-Morris J, Griffiths H, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284:2334-40.
63. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-5.
64. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002; 86:396-9.
65. Fitzgerald M, Canny M, O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill 2005; 10:050929 2.
66. Immunisation Guidelines for Ireland. National Immunisation Advisory Committee: Royal College of Physicians of Ireland 2008.
67. Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol 2007; 14:1328-33.
68. Makela PH, Kayhty H, Leino T, Auranen K, Peltola H, Ekstrom N, et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22:287-92.
69. Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002; 21:535-41. (Pubitemid 34625835)
70. White C, Halperin SA, Scheifele DW. Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines 2009; 8:831-40.
71. Howie SR, Antonio M, Akisanya A, Sambou S, Hakeem I, Secka O, et al. Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine. Vaccine 2007; 25:6305-9.
72. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008; 8:435-43.
73. Scheifele D, Law B, Mitchell L, Ochnio J. Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine 1996; 14:1399-406.
74. Decker MD, Edwards KM, Bradley R, Palmer P. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. J Pediatr 1993; 122:410-3.
75. Reid R, Santosham M, Croll J, Thompson C, Newcomer W, Siber GR. Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs. HbOC vaccine. Pediatr Infect Dis J 1993; 12:812-5.
76. Hadler SC. Cost benefit of combining antigens. Biologicals 1994; 22:415-8.
77. Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev 2009; 005530.
78. The Immunological Basis for Immunization Series. Update 2009. Geneva: World Health Organization - Immunization, Vaccines and Biologicals 2009.
79. The Immunological Basis for Immunization Series. Geneva: World Health Organization - Global Programme for Vaccines and Immunization 1993.
80. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26:6587-91.
81. Bar-Zeev N, Buttery JP. Combination conjugate vaccines. Expert Opin Drug Saf 2006; 5:351-60.